<DOC>
	<DOCNO>NCT02835794</DOCNO>
	<brief_summary>The purpose study determine safety establish maximum tolerate dose ( MTD ) omacetaxine combination azacitidine G-CSF patient relapse and/or refractory MDS .</brief_summary>
	<brief_title>A Clinical Trial Omacetaxine , Azacitidine , Growth-Colony Stimulating Factor ( G-CSF ) Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age &gt; = 18 year ; Informed consent ; Low intermediaterisk MDS fail achieve hematologic improvement least 4 cycle induction therapy relapse duration hematologic response . Prior therapy azanucleosides ( i.e. , azacitidine , decitabine ) , biologic therapy ( i.e. , lenalidomide , rigosertib ) hematopoietic cell transplant permissible ; Performance status must Eastern Cooperative Oncology Group ( ECOG ) 0 , 1 , 2 ; Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) may participate , provide meet following condition : Must agree use physicianapproved contraceptive method throughout study three month follow last dose omacetaxine Must negative serum urine pregnancy test within 7 day prior begin treatment trial ; Males female partner childbearing potential must agree use physicianapproved contraceptive method throughout study avoid conceive child 6 month follow last dose omacetaxine . Subjects eligible hematopoietic stem cell transplant ; History atrial fibrillation relate azanucleoside therapy past ; Active , uncontrolled , clinically significant infection ; Pregnant nursing patient exclude effect omacetaxine fetus nursing child unknown ; Treatment anticancer therapy ( standard investigational ) within previous 14 day prior first dose study drug le full recovery clinically significant toxic effect treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
</DOC>